Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 17

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 shares to Yorkville. As consideration for Yorkville’s irrevocable commitment to purchase shares of the Company’s common
    stock upon the terms of and subject to restrictions and satisfaction of the conditions set forth in the SEPA, upon execution of the
    SEPA, the Company issued to Yorkville 10,927 shares
    of common stock as commitment shares. Under the applicable Nasdaq Rules and pursuant to the SEPA, in no event may the Company issue
    or sell to Yorkville more than 100,830 shares
    of common stock (the “Exchange Cap”), which is 19.99%
    of the shares of common stock outstanding immediately prior to the execution of the SEPA, unless (i) the Company obtains stockholder
    approval to issue shares of common stock in excess of the Exchange Cap, or (ii) the average price of all applicable sales of common
    stock under the SEPA equals or exceeds $22.882 per
    share (which represents the lower of (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) on the trading day
    immediately preceding the effective date or (ii) the average Nasdaq Official Closing Price of the common stock (as reflected on
    Nasdaq.com) for the five trading days immediately preceding the effective date). On February 12, 2025, the Company filed a Form S-1
    covering the resale of up to 357,142 shares
    of common stock comprised of (i) 10,927 commitment
    shares, and (ii) up to 346,215 shares
    of common stock reserved for issuance and sale to Yorkville under the SEPA. The Form S-1 was declared effective on February 13,
    2025. During the first nine months of 2025, the Company sold and issued 89,902 shares
    of common stock under the SEPA for aggregate net proceeds of approximately $1.74
    million, after deducting offering expenses in the amount of approximately $0.1 million.

    d.
     
    On
    June 1, 2022, the Company entered into an ATM Agreement which was amended on September 1, 2022 with a sales agent, pursuant to which
    the Company may offer and sell, from time to time through the sales agent, shares of the Company’s common stock. The issuance
    and sale of common stock by the Company under the AT